- Home
- ESAB vs IONS Comparison
ESAB vs IONS Comparison
Compare ESAB & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- IONS
- Stock Information
- Founded
- ESAB 1904
- IONS 1989
- Country
- ESAB United States
- IONS United States
- Employees
- ESAB N/A
- IONS N/A
- Industry
- ESAB Office Equipment/Supplies/Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- ESAB Industrials
- IONS Health Care
- Exchange
- ESAB Nasdaq
- IONS Nasdaq
- Market Cap
- ESAB 6.0B
- IONS 7.0B
- IPO Year
- ESAB N/A
- IONS 1991
- Fundamental
- Price
- ESAB $97.35
- IONS $41.43
- Analyst Decision
- ESAB Buy
- IONS Buy
- Analyst Count
- ESAB 7
- IONS 18
- Target Price
- ESAB $108.57
- IONS $61.75
- AVG Volume (30 Days)
- ESAB 198.1K
- IONS 1.6M
- Earning Date
- ESAB 10-30-2024
- IONS 10-31-2024
- Dividend Yield
- ESAB 0.34%
- IONS N/A
- EPS Growth
- ESAB 18.12
- IONS N/A
- EPS
- ESAB 4.09
- IONS N/A
- Revenue
- ESAB $2,767,141,000.00
- IONS $813,460,000.00
- Revenue This Year
- ESAB N/A
- IONS N/A
- Revenue Next Year
- ESAB $4.56
- IONS $18.53
- P/E Ratio
- ESAB $22.26
- IONS N/A
- Revenue Growth
- ESAB 2.91
- IONS 29.00
- 52 Week Low
- ESAB $61.43
- IONS $35.95
- 52 Week High
- ESAB $114.77
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- ESAB 45.69
- IONS 35.13
- Support Level
- ESAB $93.45
- IONS $41.86
- Resistance Level
- ESAB $96.95
- IONS $49.08
- Average True Range (ATR)
- ESAB 2.82
- IONS 1.61
- MACD
- ESAB -0.77
- IONS -0.64
- Stochastic Oscillator
- ESAB 25.22
- IONS 8.98
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2023.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).